VALBENAZINE Drug Patent Profile
✉ Email this page to a colleague
When do Valbenazine patents expire, and when can generic versions of Valbenazine launch?
Valbenazine is a drug marketed by Lupin and Zydus Lifesciences and is included in two NDAs.
The generic ingredient in VALBENAZINE is valbenazine tosylate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the valbenazine tosylate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Valbenazine
A generic version of VALBENAZINE was approved as valbenazine tosylate by LUPIN on April 5th, 2024.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for VALBENAZINE?
- What are the global sales for VALBENAZINE?
- What is Average Wholesale Price for VALBENAZINE?
Summary for VALBENAZINE
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| DailyMed Link: | VALBENAZINE at DailyMed |
US Patents and Regulatory Information for VALBENAZINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lupin | VALBENAZINE TOSYLATE | valbenazine tosylate | CAPSULE;ORAL | 216064-001 | Apr 5, 2024 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Zydus Lifesciences | VALBENAZINE TOSYLATE | valbenazine tosylate | CAPSULE;ORAL | 216137-002 | Aug 7, 2024 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Lupin | VALBENAZINE TOSYLATE | valbenazine tosylate | CAPSULE;ORAL | 216064-002 | Apr 5, 2024 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Zydus Lifesciences | VALBENAZINE TOSYLATE | valbenazine tosylate | CAPSULE;ORAL | 216137-001 | Aug 7, 2024 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Zydus Lifesciences | VALBENAZINE TOSYLATE | valbenazine tosylate | CAPSULE;ORAL | 216137-003 | Aug 7, 2024 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
